Literature DB >> 10197599

The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development.

T H Rabbitts1, K Bucher, G Chung, G Grutz, A Warren, Y Yamada.   

Abstract

Two general features have emerged about genes that are activated after chromosomal translocations in acute forms of cancer. The protein products of these genes are transcription regulators and are involved in developmental processes, and it seems that the subversion of these normal functions accounts for their role in tumorigenesis. The features of the LMO family of genes, which encode LIM-domain proteins involved in T-cell acute leukemia through chromosomal translocations, typify these abnormal functions in tumorigenesis. For example, the LMO2 protein is involved in the formation of multimeric DNA-binding complexes, which may vary in composition at different stages of hematopoiesis and function to control differentiation of specific lineages. In T cells, enforced expression of Lmo2 causes aberrant protein complex formation that primarily seems to hinder the T-cell differentiation program. These observations underscore the conclusion that protein-protein interaction (in this case, through the LIM domain) is a key determinant in tumorigenesis. Furthermore, the study of chromosomal translocations as naturally occurring mutations has been informative about mechanisms in hematopoiesis as well as in tumor etiology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197599

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  The zinc-finger proto-oncogene Gfi-1b is essential for development of the erythroid and megakaryocytic lineages.

Authors:  Shireen Saleque; Scott Cameron; Stuart H Orkin
Journal:  Genes Dev       Date:  2002-02-01       Impact factor: 11.361

2.  The ubiquitin ligase Rnf6 regulates local LIM kinase 1 levels in axonal growth cones.

Authors:  Baris Tursun; Anne Schlüter; Marvin A Peters; Birte Viehweger; Heather P Ostendorff; Juliana Soosairajah; Alexander Drung; Michael Bossenz; Steven A Johnsen; Michaela Schweizer; Ora Bernard; Ingolf Bach
Journal:  Genes Dev       Date:  2005-10-01       Impact factor: 11.361

3.  The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.

Authors:  Y Yamada; R Pannell; A Forster; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Integrative genomics identifies LMO1 as a neuroblastoma oncogene.

Authors:  Kai Wang; Sharon J Diskin; Haitao Zhang; Edward F Attiyeh; Cynthia Winter; Cuiping Hou; Robert W Schnepp; Maura Diamond; Kristopher Bosse; Patrick A Mayes; Joseph Glessner; Cecilia Kim; Edward Frackelton; Maria Garris; Qun Wang; Wendy Glaberson; Rosetta Chiavacci; Le Nguyen; Jayanti Jagannathan; Norihisa Saeki; Hiroki Sasaki; Struan F A Grant; Achille Iolascon; Yael P Mosse; Kristina A Cole; Hongzhe Li; Marcella Devoto; Patrick W McGrady; Wendy B London; Mario Capasso; Nazneen Rahman; Hakon Hakonarson; John M Maris
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

5.  Tandem LIM domains provide synergistic binding in the LMO4:Ldb1 complex.

Authors:  Janet E Deane; Daniel P Ryan; Margaret Sunde; Megan J Maher; J Mitchell Guss; Jane E Visvader; Jacqueline M Matthews
Journal:  EMBO J       Date:  2004-09-02       Impact factor: 11.598

Review 6.  Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Authors:  Kathleen A Maguire-Zeiss; Howard J Federoff
Journal:  J Neuroimmune Pharmacol       Date:  2008-10-18       Impact factor: 4.147

7.  A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.

Authors:  Linda Scobie; Ralph D Hector; Louise Grant; Margaret Bell; Anne A Nielsen; Sharon Meikle; Adrian Philbey; Adrain Philbey; Adrian J Thrasher; Adrain J Thrasher; Ewan R Cameron; Karen Blyth; James C Neil
Journal:  Mol Ther       Date:  2009-03-31       Impact factor: 11.454

Review 8.  Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options.

Authors:  Suk See De Ravin; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 4.505

Review 9.  In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application.

Authors:  Graça Almeida-Porada; Anthony Atala; Christopher D Porada
Journal:  Mol Ther Methods Clin Dev       Date:  2016-03-30       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.